Reply to'Resistant hypertension revisited: Definition and true prevalence'

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1547-

  Smith, Steven M ^a,b   Pepine, Carl J ^c   Cooper DeHoff, Rhonda M ^a,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Department of Community Health and Family Medicine ^*  (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADVERSE OUTCOME; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; HUMAN; INCIDENCE; LETTER; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; COMPLICATION; CORONARY ARTERY DISEASE; FEMALE; HYPERTENSION; MALE;

CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 84903852937     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000220     Document Type: Letter

References (8)

1. Modolo R, de Faria AP, Sabbatini AR, Moreno H. Resistant hypertension revisited: Definition and true prevalence. J Hypertens 2014; 32:1546.
2. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens 2014; 32:635-643.
3. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
4. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension: Its identification and epidemiology. Nat Rev Nephrol 2013; 9:51-58.
5. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393-404.
6. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290:2805-2816.
7. Bakhtar O, Ference BA, Hedquist LA, Levy PD, Flack JM. Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort. J Clin Hypertens (Greenwich) 2012; 14:618-622.
8. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1045-1058.